Dr Lal Pathlabs

Dr Lal Pathlabs recorded a 10.7% YoY revenue growth in Q2 FY26, reaching ₹731 crore. This was supported by a 10.3% increase in sample volumes to 25.4 million and a 5% rise in patient volumes to 8.2 million. Management noted that while core growth was strong, overall volumes were moderated by a lower incidence of seasonal illnesses like Dengue and Malaria compared to the previous year. Despite this, revenue per patient improved by 5.4% to ₹889, reflecting a better test mix and the success of the Swasthfit program.

The company is successfully piloting high-end radiology services (CT and MRI) in Delhi NCR and plans to expand this to more centers within the current financial year. Management indicated that the investment for these centers is lower than the industry average of ₹20-25 crore because they are leveraging existing infrastructure. Additionally, the Genevolve division is enhancing capabilities in molecular diagnostics and personalized medicine, while the integration of AI modules for cancer detection underscores their leadership in new-age diagnostics.

Q2 EBITDA margins were robust at 30.7%, though management maintained a full-year guidance of 27-28% to account for planned investments in the second half. Total CAPEX for FY26 is estimated at ₹130-140 crore, which includes ₹75 crore for property acquisition in Shalimar Bagh to enhance super-specialty testing capabilities. The company is also passing on GST benefits from reduced rates on reagents to customers, which precludes immediate price hikes but supports organic volume growth.

Management emphasized that new network points take time to reach the productivity levels of established labs. They are maintaining a disciplined cluster-based expansion, with a renewed focus on Delhi NCR, which has responded with double-digit growth. The company plans to add 15-20 new labs and 600-800 collection centers in FY26. The Suburban IT integration in the West is now complete, with management expecting a return to double-digit growth in that geography by Q4 FY26.

Reflecting strong operational performance and a healthy cash balance of ₹1,367 crore, the Board approved a 1:1 bonus issue and an interim dividend of ₹7 per share. Management stated that their B2C contribution remains high at approximately 75% of total revenue, and they are not actively seeking to increase this ratio further, viewing it as a 'reasonably good' level. The focus remains on driving sustainable, long-term growth through geographic expansion and portfolio innovation.